中文摘要：

使用抗VEGF药物是目前临床治疗新生血管性AMD的主要方式之一,但是在规范化治疗中,很多患者对治疗的反应各不相同,部分患者出现多次复发,甚至有的患者对治疗不敏感.目前对于抗VEGF药物治疗后的各种临床反应和现象没有明确的标准和定义,因此临床亟需规范统一相关概念.明确归纳和区分机体对于抗VEGF药物的治疗反应,探索新的换药方案,对临床治疗新生血管性AMD具有重要的临床指导意义.

英文摘要：

Anti-VEGF therapy is currently one of the main treatments for neovascular age-related macular degeneration （nAMD）.Clinically, patients under standardized anti-VEGF therapy showed different responses, of which recurrences or even insensitivity were found in some patients.However, the specific definitions of these various clinical responses are still unclarified.Therefore, to consolidate and define these concepts are of great importance regarding to future efficacy comparison, treatment response clarification and novel drug switching therapies.